You are here

  • Home
  • Archive
  • Volume 85, Issue Suppl 1
  • M17 Targeting Dopamine D1-histamine H3 Receptor Heteromers As A Therapeutical Strategy To Prevent Cognitive Deficits And Neurodegeneration In Huntington’s Disease

Article info

Article menu
Download PDFPDF
Experimental therapeutics – preclinical
M17 Targeting Dopamine D1-histamine H3 Receptor Heteromers As A Therapeutical Strategy To Prevent Cognitive Deficits And Neurodegeneration In Huntington’s Disease

Authors

  • MP Cañadell 1Department of Cellular Biology, Immunology and Neuroscience, Faculty of Medicine, University of Barcelona, Spain2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas PubMed articlesGoogle scholar articles
  • D Moreno-Delgado 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain PubMed articlesGoogle scholar articles
  • M Rodríguez-Ruiz 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain PubMed articlesGoogle scholar articles
  • E Moreno 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain PubMed articlesGoogle scholar articles
  • J Botta 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain PubMed articlesGoogle scholar articles
  • P Gasperini 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain4School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ PubMed articlesGoogle scholar articles
  • A Cordomí 5National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224 Maryland, USA PubMed articlesGoogle scholar articles
  • LA Howell 4School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ PubMed articlesGoogle scholar articles
  • G Navarro 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain PubMed articlesGoogle scholar articles
  • V Casadó 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain PubMed articlesGoogle scholar articles
  • S Ferré 5National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224 Maryland, USA PubMed articlesGoogle scholar articles
  • M Guzmán 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas6Department of Biochemistry and Molecular Biology I, School of Biology, Computense University of Madrid, Spain PubMed articlesGoogle scholar articles
  • L Pardo 7Computational Medicine Laboratory, Faculty of Medicine, Autonomous University of Barcelona, Bellaterra, Spain PubMed articlesGoogle scholar articles
  • J Alberch 1Department of Cellular Biology, Immunology and Neuroscience, Faculty of Medicine, University of Barcelona, Spain2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas PubMed articlesGoogle scholar articles
  • EI Canela 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain PubMed articlesGoogle scholar articles
  • C Lluís 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain PubMed articlesGoogle scholar articles
  • P J McCormick 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain4School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ PubMed articlesGoogle scholar articles
  • S Ginés 1Department of Cellular Biology, Immunology and Neuroscience, Faculty of Medicine, University of Barcelona, Spain2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas PubMed articlesGoogle scholar articles

Citation

Cañadell M, Moreno-Delgado D, Rodríguez-Ruiz M, et al
M17 Targeting Dopamine D1-histamine H3 Receptor Heteromers As A Therapeutical Strategy To Prevent Cognitive Deficits And Neurodegeneration In Huntington’s Disease
Journal of Neurology, Neurosurgery & Psychiatry 2014;85:A100.

Publication history

  • First published September 17, 2014.
Online issue publication 
February 26, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions